Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2018 / N 4

Современные возможности снижения риска развития сахарного диабета 2-го типа и сердечно-сосудистых осложнений у больных с предиабетом
Ю.А. Карпов, А.Т. Шубина

Список литературы

1. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. The Lancet 2012 Jun;379(9833):2279-90.
2. Shubina AT, Demidova IYu, Karpov YuA. Metabolic syndrome X: predisposition to hypertension and atherosclerosis development. Part 1. Clinical Pharmacology and Therapy 2001;10(4):44-7 (In Russian).
3. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009 Oct;120(16):1640-5.
4. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL; ESC Committee for Practice Guidelines (CPG); Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers; De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal 2013 Oct;34(39):3035-87.
5. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabetic Medicine 2002 Sep;19(9):708-23.
6. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004 Dec;53(Suppl 3):S16-21.
7. Standards of medical care in diabetes. Dedov II, Shestakova MV, Mayorov AYu, editors. 8th edition. Diabetes Mellitus 2017;20(Suppl 1):1-121 (In Russian).
8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011 Jan;34(Suppl 1):S62-9.
9. Dedov I, Shestakova M, Benedetti MM, Simon D, Pakhomov I, Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice 2016 May;115:90-5.
10. Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, Kodama S, Hsieh SD, Mori Y, Shimano H, Yamada N, Kosaka K, Sone H. HbA1c 5,7–6,4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. The Lancet 2011 Jun;378:147-55.
11. Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, Yazdi H, Booker L. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Research and Clinical Practice 2007 Dec;78(3):305-12.
12. Pareek M, Bhatt DL, Nielsen ML, Jagannathan R, Eriksson KF, Nilsson PM, Bergman M, Olsen MH. Enhanced predictive capability of a 1-hour oral glucose tolerance test: a prospective population-based cohort study. Diabetes Care 2018 Jan;41(1):171-7.
13. Fiorentino TV, Marini MA, Andreozzi F, Arturi F, Succurro E, Perticone M, Sciacqua A, Hribal ML, Perticone F, Sesti G. One-hour postload hyperglycemia is a stronger predictor of type 2 diabetes than impaired fasting glucose. The Journal of Clinical Endocrinology & Metabolism 2015 Oct;100(10):3744-51.
14. Armato JP, DeFronzo RA, Abdul-Ghani M, Ruby RJ. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). The Lancet. Diabetes & Endocrinology 2018 Sep;6(10):781-9.
15. Karpov YuA, Shubin AT. Metformin treatment of patients with metabolic syndrome and type 2 diabetes mellitus. Russian Medical Journal 2010;18(22):1312-4 (In Russian).
16. Björntorp P. Obesity. Lancet 1997 Aug;350(9075):423-6.
17. Sardu C, Paolisso P, Sacra C, Mauro C, Minicucci F, Portoghese M, Rizzo MR, Barbieri M, Sasso FC, D’Onofrio N, Balestrieri ML, Calabrò P, Paolisso G, Marfella R. Effects of metformin therapy on COronary endothelial DYsfunction in prediabetic patients With stable angina and Non Obstructive Coronary Artery Stenosis: the CODYCE multicenter prospective study. Diabetes Care 2019 Feb 22. pii: dc182356. doi: 10.2337/dc18-2356. [Epub ahead of print].
18. Valensi P, Extramiana F, Lange C, Cailleau M, Haggui A, Maison Blanche P, Tichet J, Balkau B; DESIR Study Group. Influence of blood glucose on heart rate and cardiac autonomic function. The DESIR study. Diabetic Medicine 2011 Apr;28(4):440-9.
19. Schroeder EB, Chambless LE, Liao D, Prineas RJ, Evans GW, Rosamond WD, Heiss G; Atherosclerosis Risk In Communities (ARIC) study. Diabetes, glucose, insulin and heart rate variability: the Atherosclerosis Risk In Communities (ARIC) study. Diabetes Care 2005 Mar;28(3):668-74.
20. Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet 2010 Jun;375(9733):2215-22.
21. National Institute for Health and Care Excellence (NICE). Type 2 diabetes: prevention in people at high risk. Public health guideline [PH38]. Published date: July 2012. Last updated: September 2017. Available from: https://www.nice.org.uk/guidance/ph38/chapter/Recommendations Accessed 2018 Dec 12.
22. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. The New England Journal of Medicine 1995 Aug;333(9):550-4.
23. Scheen AJ, Letiexhe MR, Lefebvre PJ. Effects of metformin in obese patients with impaired glucose tolerance. Diabetes/Metabolism Research and Reviews 1995;11(Suppl 1):S69-80.
24. Bailey CJ. Metformin and intestinal glucose handling. Diabetes/Metabolism Research and Reviews 1995;11(Suppl 1):S23-32.
25. De Fronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. The Journal of Clinical Endocrinology and Metabolism 1991 Dec;73(6):1294-301.
26. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, André P, Isnard F, Cohen JM, Grandmottet P, Vague P, Safar ME, Eschwège E. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996 Sep;19(9):920-6.
27. Montaguti U, Celin D, Ceredi C, Descovich GC. Efficacy of the long-term administration of metformin in hyperlipidaemc patients. Research and Clinical Forums 1979;1:95-103.
28. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, D’Onofrio F. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. European Journal of Clinical Pharmacology 1993;44(2):107-12.
29. Bhalla RC, Toth KF, Tan E, Bhatty RA, Mathias E, Sharma RV. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. American Journal of Hypertension 1996 Jun;9(6):570-6.
30. Shubina AT, Demidova IYu, Karpov YuA. Metformin and circadian pattern of blood pressure in patients with metabolic syndrome X. International Journal of Medical Practice 2001;1:33-5 (In Russian).
31. Kobalava ZhD, Kotovskaya YuV. Daily profile of blood pressure in patients with hypertension and metabolic disorder. Clinical Pharmacology and Therapy 1995;4(3):50-1 (In Russian).
32. Peuler JD, Miller JA, Bourghli M, Zammam HY, Soltis EE, Sowers JR. Disparate effects of antidiabetic drugs on arterial contraction. Metabolism 1997 Oct;46(10):1199-205.
33. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine 2002 Feb;346(6):393-403.
34. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006 Feb;49(2):289-97.
35. UK Prospective Diabetes Study (UKPDS) Group. Effect of blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998;352:854-65.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]